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ABSTRACT
Introduction: Vascular access devices (VADs), such as
peripheral or central venous catheters, are vital across all
medical and surgical specialties. To allow therapy or
haemodynamic monitoring, VADs frequently require
administration sets (AS) composed of infusion tubing,
fluid containers, pressure-monitoring transducers and/or
burettes. While VADs are replaced only when necessary,
AS are routinely replaced every 3–4 days in the belief that
this reduces infectious complications. Strong evidence
supports AS use up to 4 days, but there is less evidence
for AS use beyond 4 days. AS replacement twice weekly
increases hospital costs and workload.
Methods and analysis: This is a pragmatic,
multicentre, randomised controlled trial (RCT) of
equivalence design comparing AS replacement at 4
(control) versus 7 (experimental) days. Randomisation is
stratified by site and device, centrally allocated and
concealed until enrolment. 6554 adult/paediatric patients
with a central venous catheter, peripherally inserted
central catheter or peripheral arterial catheter will be
enrolled over 4 years. The primary outcome is VAD-
related bloodstream infection (BSI) and secondary
outcomes are VAD colonisation, AS colonisation, all-
cause BSI, all-cause mortality, number of AS per patient,
VAD time in situ and costs. Relative incidence rates of
VAD-BSI per 100 devices and hazard rates per 1000
device days (95% CIs) will summarise the impact of 7-
day relative to 4-day AS use and test equivalence. Kaplan-
Meier survival curves (with log rank Mantel-Cox test) will
compare VAD-BSI over time. Appropriate parametric or
non-parametric techniques will be used to compare
secondary end points. p Values of <0.05 will be
considered significant.
Ethics and dissemination: Relevant ethical approvals
have been received. CONSORT Statement
recommendations will be used to guide preparation of
any publication. Results will be presented at relevant
conferences and sent to the major organisations with
clinical practice guidelines for VAD care.
Trial registration number: Australian New Zealand
Clinical Trial Registry (ACTRN 12610000505000).
INTRODUCTION
Vascular access devices (VADs) are small
hollow catheters inserted into a vein or artery.
VAD insertion is the most common invasive
healthcare procedure with approximately 14
million VADs used in Australia each year and
billions throughout the world.1 VADs are
inserted either centrally (eg, central venous
catheter (CVC)) or peripherally (eg, periph-
erally inserted central venous catheter
(PICC)) for haemodynamic monitoring and
the delivery of intravascular fluids, nutrition
and medications. VADs also include periph-
eral arterial catheters (PAC) used predomin-
antly in the operating theatre and critical care
units to provide continuous blood pressure
monitoring and access for repeated blood
sampling. In order to deliver many therapies,
VADs require connection to an administration
set (AS). The AS refers to infusion systems
comprised of some or all of tubing, fluid con-
tainers, pressure monitoring transducers,
blood sampling ports, measuring burettes,
extension tubing and needleless connectors.
VADs break the natural defence barrier of the
skin and are the single most important cause
of healthcare-acquired bloodstream infection
(BSI). About 250 000–500 000 VAD-BSIs
occur each year in the USA alone.2 VAD-BSIs
are associated with increased mortality and
substantially increase hospital stay and
Rickard CM, et al. BMJ Open 2015;5:e007257. doi:10.1136/bmjopen-2014-007257 1
Open Access Protocol
group.bmj.com on July 21, 2015 - Published by http://bmjopen.bmj.com/Downloaded from 
treatment costs by up to 20 days and US$56 000/episode,
respectively.2
Clinicians traditionally limit the duration of AS use by
routinely replacing AS at regular intervals. That is, the
VAD may be used for a week or more, whereas the AS is
routinely disconnected, discarded and replaced every
3–4 days. The practice of routinely changing AS is not
based on strong evidence of efficacy. Prior to the 1970s,
AS were used until no longer required.3 4 Routine AS
replacement developed as a response to the 1970–1971
USA epidemic of VAD-BSI; this epidemic was later traced
to manufacturer-contaminated intravenous fluid.3 5
Despite the unrelated nature of this cause to the duration
of AS use, 24 h routine replacement of AS was advocated
and universally implemented at that time.6 7 The policy
of routine replacement has continued since.
VAD AS replacement at 24–96 h
Each AS replacement involves significant nursing time and
costs up to $A300 (2004) for one VAD AS change in equip-
ment alone.8 Since 1971, the length of time between AS
changes has gradually been extended. Several randomised
controlled trials (RCTs) compared time frames such as 24
versus 48 h or 24 versus 72 h. A Cochrane Collaboration
systematic review and meta-analysis of 16 RCTs included
5001 patients and AS use of 24 to ≥96 h.9 No significant
difference was found in VAD-BSI with longer periods of AS
use. In addition, no significant effect was found on any of
the device colonisation, infusate colonisation, infusate-
related BSI or all-cause BSI. There was some evidence that
less frequent AS replacement increased mortality rate in
neonates (RR 1.84; 95% CI 1.00 to 3.66). This was based
on two studies of 24 versus 48 h AS replacement10 and 24
versus 72 h replacement,11 with 96% of the statistical
weight coming from the latter study which was at risk of
bias from a suboptimal randomisation technique (10% of
sample were rerandomised).
VAD AS use beyond 96 h
The Cochrane Review found inadequate trials to investi-
gate AS use beyond 96 h.9 One RCT (512 patients) com-
pared 3-day with ‘between 4-day and 7-day’ use and found
no significant difference in infusate-related BSI.12 An
unpublished conference abstract reported another RCTof
769 patients with AS replaced at 72 or 120 h, with no
between-group differences in catheter colonisation or
VAD-BSI.13 Jakobsen et al14 undertook a five-group RCT
with AS changed at 24, 48, 72, 96 or 120 h and found no
difference in catheter colonisation. Luskin et al15 rando-
mised 112 patients to have AS changes at 48, or 96 h to
192 h and reported no difference in infusate colonisation,
infusate-related BSI or device colonisation. In vitro work
found AS retained accuracy for volume delivery and good
physical condition after 7 days continuous use.16 Clinical
studies have demonstrated identical rates of VAD-BSI and
no significant difference in VAD colonisation when AS
were replaced at 3–4 days or 7 days,8 17 with substantial
cost savings in AS and nursing time,17 and no relationship
between infusate colonisation or VAD-BSI and time.18
Clinical practice guidelines and expert recommendations
Joint guidelines from Healthcare Epidemiology and the
Infectious Diseases Societies of America cite the Cochrane
review9 and recommend replacing AS at ‘not longer than
96 h intervals’.19 20 Australia’s Infection Prevention
Guidelines also recommended maximum 4-day use.21 The
Centers for Disease Control and Prevention (CDC)
‘Guidelines for the Prevention of VAD Related
Infections’22 recommends changing AS ‘no more fre-
quently than every 96 h, but at least every 7 days’. This
highlights the uncertainty of relative risk between these
two time frames. All AS guidelines exclude high growth
media of lipid-based and blood-based AS infusions which
are discarded within 24 h.
Theoretical framework for AS replacement
The theoretical principle behind routine AS replacement
is that AS are initially sterile and become contaminated
through clinical use, but if removed at set intervals, BSI is
prevented.23 Limiting AS use to 4 days presumes microbes
within sets are not problematic before day 4 and ignores
the potential for immediate microbial contamination
when staff inject medicine or fluids. It seems likely that if
an AS is contaminated, virulent pathogens would cause
significant growth and patient infection within a shorter
time; thus, fourth day replacement would have no effect
on pathogens already infused.15 24
Routine AS replacement itself provides an opportunity
for contamination, as it breaks a closed circuit, and this
suggests it should actually be avoided.25 Increased occa-
sions of AS manipulations are known to increase infec-
tion, yet routine replacement causes extra handling of
the hub and AS.6 26 Poor aseptic technique in accessing
the AS is not uncommon27 and would likely over-ride
any benefit of routine AS replacement. Further, AS
replacement does not replace the hub component of
the VAD itself, which is known to be the main reservoir
for infection from VADs after the first week.28 The
current incongruous situation is that VADs are used for
extended periods and only removed for VAD-BSI or at
completion of treatment, yet the AS are disconnected
and replaced twice each week.
VADs are vital and ubiquitous medical devices, with bil-
lions used around the world each year. Consequently, reli-
able evidence that informs the safe, effective use of these
devices is important to patients, nurses, doctors and the
community. The aim of the study is to compare the impact
of VAD AS replacement at 4 versus 7 days on infective, clin-
ical and cost outcomes. The primary hypothesis is that
there will be equivalence in the incidence of VAD-BSIs
between patients assigned to AS replacement at 4 versus
7 days. We also hypothesise that there will be equivalence
between groups in the incidence of: (1) AS colonisation,
(2) hub colonisation, (3) VAD colonisation, (4) all-cause
BSI rate, (5) VAD time in situ, and (6) all-cause mortality;
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and that patients assigned to 4-day replacement will have
significantly higher: (1) number of AS used and (2) asso-
ciated healthcare costs.
METHODS AND ANALYSIS
The study is a pragmatic, multicentre, RCT of equivalence
design. Adult and paediatric patients with a CVC, PICC or
PAC will be enrolled. The experimental group will have AS
routinely replaced every 7 days and the control group
every 4 days. There will be a 4-year recruitment period of
6554 patients. The protocol is V.3 dated 17 February 2014.
Outcome measures
Primary outcome
VAD-BSI
1. Primary bacteraemia/fungaemia with ≥1 positive
blood culture from a peripheral vein with no other
identifiable source for the BSI other than the VAD,
plus a positive semiquantitative (>15 colony forming
units (CFU)) device culture, with the same organism
(species and antibiogram) isolated from the device
tip and the blood;2 22
or
2. Two blood cultures (one from a VAD and one from a
peripheral vein) that meet the VAD-BSI criteria for
differential time to positivity (DTP) (growth of the
same microbe from hub-drawn blood at least 2 h
before growth from the peripheral blood).29
Criterion 1 is generally used for diagnosis in short-term
catheters (CVCs and PACs) where the device is com-
monly removed when infection is suspected. Criteria 2 is
generally used for diagnosis in long-term CVCs and
PICCs where the device is often left in situ when infection
is suspected. The original study protocol (as listed in the
trial registry when started) included additional options
for diagnosis of the Primary Outcome using blood and
tip culture results using quantitative laboratory culture
methods. These were deleted at a later stage since none
of the study sites use quantitative blood or tip culture
techniques in their hospital laboratories.
Secondary outcomes
A. VAD colonisation: Growth of >15 CFU from distal
segment of VAD tip on removal, using the semiquan-
titative culture method.30 31 The original trial proto-
col in the registry also listed an option for diagnosis
using quantitative culture results. This option was
deleted at a later stage since none of the study sites
use quantitative blood or tip culture techniques in
their hospital laboratories.
B. AS colonisation: Growth of ≥103 CFU/mL from the AS
using quantitative culture.32 33 This end point is per-
formed in the research laboratory (not the hospital
laboratory) where quantitative methods are available.
C. All-cause BSI: A bacteraemia or fungaemia obtained
from a peripheral vein and taken while the VAD is in
situ, or within 48 h of removal.31
D. All-cause mortality: Mortality at hospital discharge.
E. Time in situ: Hours of device use from insertion to
removal.31
F. AS per patient: Number of AS used from the time of
study entry to discharge from hospitalisation.
G. Costs: AS consumable prices, staff time and treatment
costs for VAD-BSI.34
Setting and sample
The trial will be undertaken at eight major hospitals in
Australia. The study hospitals together have over 500 000
separations per annum, and cover the full range of
medical and surgical specialties. Adult and paediatric
patients admitted to acute medical, surgical, oncology,
haematology and critical care wards will be screened.
Inclusion criteria are informed written or documented
verbal consent (if need for consent not waived by the
Human Research Ethics Committee (HREC) for that
hospital), central venous (including PICCs) and/or per-
ipheral arterial VAD in situ with AS, VAD in situ for
>24 h, and VAD scheduled/expected use ≥7 days.
Exclusion criteria are BSI within previous 48 h, planned
removal of device ≤24 h, VAD in situ >96 h, and original
AS already routinely replaced.
Sample size
Sample size calculations determined that 1371 CVCs, 1268
PICCs and 340 PACs are required per group (total VADs
2979 per group) for >90% power at p=0.05 (PASS, Power
Analysis and Sample Size system, NCSS, Utah, USA). The
proportion of VAD-BSI in the reference (control) group is
estimated to be 2.6%, 2.4% and 0.8% for CVC, PICC and
PAC, respectively, taken from a metasynthesis of VAD-BSI
rates in >2 million VADs—using identical definitions as in
our study.2 22 A cumulative approach was used for the
three device types (CVC, PICC, PAC). To allow for poten-
tial attrition, a further 10% (298 VADs) will be recruited
per group. An equivalence hypothesis was used for CVCs
and PICCs with ±2% limits. As PAC rates are already
extremely low (0.8%), a non-inferiority approach was used
(+2% bound). The 2% margin reflects all previous well-
designed RCTs on the topic of AS duration, with absolute
differences between groups of −1.7% to 1.3%. The two
prior RCTs8 12 that tested 3-day/4-day use with 7-day use
observed identical absolute rates of VAD-BSI in the two
groups. Raad et al12 also used 2% bounds for equivalence.
Based on our pilot and the Cochrane review,8 9 we con-
sider >2% difference in the primary end point between
groups to be very unlikely.
Recruitment and randomisation
The medical, surgical, haematology–oncology wards and
intensive care units (ICU) will be screened at least
3 days each week by dedicated research nurses and all
eligible patients (or their representative) will be
approached for informed consent (except in hospitals
where the requirement for consent has been waived by
the local HREC). Patients will be randomly assigned,
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using computer-generated random assignment in a 1:1
ratio, to either the 4-day AS change group or 7-day AS
change group. This will be stratified by device type
(short-term CVC, long-term CVC, PICC or PAC), acuity
(ICU and non-ICU), and hospital site to ensure equal
distribution of patient and therapy types between
groups. As randomisation will be conducted via a centra-
lised computer randomisation service, allocation will be
concealed until the point of randomisation.
Replacement and care of AS
The experimental group will have all AS changed on day
7, and then weekly, by clinical staff. The control group will
have AS changed by clinical staff every 4 days. In both
groups, additional AS reconfiguration will occur if clinic-
ally indicated due to treatment addition/completion, VAD
removal or AS malfunction. AS configurations, number,
timing and reason for AS changes will be documented.
VADs will be removed at the decision of the treating clin-
ician. Clinical staff will be responsible for the insertion and
care of VADs and AS following CDC Guidelines, including
discard of any AS used for chemotherapy immediately
after use and blood-based or lipid-based products within
12 and 24 h, respectively.31 Protocol adherence will be
monitored by the research nurses, with breaks in the
protocol documented. Once the VAD is removed (even if
replaced by guidewire into the same vein), or continuous
infusions have been ceased for the three study visits, the
patient has completed the study (with the exception of the
48 h follow-up).
Microbiological testing and end points
Blood and VAD tip cultures will be taken by clinical staff
on suspicion of infection as per usual hospital and path-
ology department protocols. It is well validated that it is
unnecessary to culture non-symptomatic patients’
samples routinely, as almost identical rates of VAD-BSI
are achieved with culture only on clinical suspicion.2 All
patients with a BSI while the VAD is in situ (+48 h post-
removal) will have a standardised data collection sheet
(that includes all data necessary for VAD-BSI diagnosis
as per the CDC definitions but does not reveal the study
group) prepared by the research nurses. This data will
then be reviewed by one of the blinded investigators
(EGP) who is an infectious diseases specialist familiar
with the diagnosis and treatment of VAD-BSI. This inves-
tigator will assign the primary end point of VAD-BSI and
nominate the likely source (VAD, AS, skin or haema-
togenous seeding). The blinded hospital microbiology
staff will assign the secondary end points of BSI and
device colonisation, using objective measures and tech-
niques that are routine daily procedures.30 For the sec-
ondary end points of hub and AS colonisation, a
random subset of 325 patients per group whose VAD are
removed for suspected VAD-BSI and 325 patients per
group without suspected VAD-BSI (total 20% of sample)
will have AS samples cultured.35 The specimens will be
processed by scientists with expertise in such bacterial
counts and identification.32 33 These end points will be
of interest regarding potential pathogenic impact of AS
replacement timing. It would be unfeasible and prohibi-
tively expensive to perform these for the whole sample
and also unnecessary, given that our primary interest is
the effectiveness of the intervention to prevent clinical
infection.
Blinding
This trial is blinded for the primary end point of
VAD-BSI and for the secondary end points of AS, device
and hub colonisation. These are performed by blinded
infectious disease and microbiologists. AS replacement
procedures and the time frames will not be possible to
conceal from patients, research nurses or clinical staff.
However, as they are not assessing the primary end point
this will not introduce bias.
Data collection
The research nurses, all of whom have had study-specific
database training, will directly enter data in the clinical
areas using hand-held password-protected electronic
devices with a purpose-built Access database and
form-based interface or using REDCap (project-redcap.
org). This technology is well established in our group. All
data is de-identified at this point and only identifiable
within the database by specific study number. The master
list of participants will be kept separate to the study data-
base in a different password-protected computer pro-
gramme. Baseline data will include age, gender, diagnostic
group, severity of infection risk and immunosuppression
status.36–38 Other data collected will be the concurrent
infection, antibiotic therapy, type of infusate and additives,
VAD type, insertion site, inserter, VAD dwell time, AS hang
time, reason for VAD and AS removal, and mortality
status.6 19 37 AS configuration at the time of AS recruit-
ment and at each replacement will be noted.
Microbiological data will include BSI, VAD and other cul-
tures taken during AS use and for 48 h postremoval if
patients are still in hospital. Some patients in each group
will cease VAD therapy for clinical reasons <96 h (eg,
deceased). Outcome data will be collected for these cases
and included in the final analysis.
Data analysis
Intention to treat analysis will be used and the patient is
the unit of measurement (patient randomised once but
may have multiple VADs and AS). Relative incidence rates
of VAD-BSI per 100 devices and hazard rates per 1000
device days with 95% CIs will summarise the impact of
the 7-day relative to 4-day AS use and test equivalence for
CVCs, PICCs and PACs. Kaplan-Meier survival curves
(with log rank Mantel-Cox test) will compare VAD-BSI
rates over time. Subgroup analysis will be stratified by
VAD type. Secondary end points will be compared
between groups using parametric or non-parametric
techniques appropriate to level of measurement.
Secondary analysis using multivariate regression (Cox)
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will test the effect of variables associated with VAD-BSI
risk on the outcome: lipids, parenteral nutrition, antibio-
tics, length of stay, diagnostic group, initial versus subse-
quent VADs, age, gender, VAD-BSI in a preceding
catheter, site of VAD placement, inserter and patient risk
category. All possible attempts will be made to collect the
primary end point. Missing data will be modelled for best-
case and worst-case outcomes to assess any potential
effect on overall results and a per-protocol analysis will
assess the effect of protocol violations. p Values of <0.05
will be considered significant. We do not expect effect
sizes to vary between sites; however, intersite variability
will be assessed and if necessary, adjustment is made in
the model, with consideration of potential institutional
differences in patient variables.
Estimating cost parameters
Procedure costs will be measured by assessing the staff
time associated with AS change, and the type and
volume of equipment used.32 33 The economic oppor-
tunity costs of workers’ time will be valued by national
wage rates to include full costs of employment; costs of
equipment will be valued based on standard contracts
between state health services and commercial manufac-
turers. Mean costs of 7-day and 4-day changes will be
compared to identify the likely cost savings of a decision
to make 7-day changes standard practice.
Time frame and feasibility
It is expected that, with staggered site start-ups, recruit-
ment will be 4 years, 6 months. We will implement trial-
specific education to ensure clinical staff support for the
study and protocol adherence. To test if the 4-day and
7-day replacement are equivalent, it is crucial that
adequate numbers of AS are used beyond this point. It
is expected that a small number of VADs in both groups
will be removed before scheduled AS replacement; this
reflects the real world of clinical practice and will not
limit generalisability.
MONITORING, ETHICS AND DISSEMINATION OF RESULTS
Monitoring
Study managers (NMM and ER) who report to the chief
investigator (CMR) and are employed by the sponsor
(Griffith University), provide initial training and
ongoing support to the research nurses and site investi-
gators, and monitor data quality and site processes, at
least monthly.
Ethical and safety considerations
Both 4-day and 7-day AS use is within the recommenda-
tions of the CDC and the Cochrane Collaboration.
Seven-day AS use has been used in some hospitals since
the completion of our pilot study, and other reports also
support its safety.8 12 17 18 Participants or representatives
may give either written or documented verbal consent or
the consent may be waived depending on processes
acceptable at each hospital under the relevant State legisla-
tion. For paediatrics, as per the National Statement on
Ethical Conduct in Human Research, consent will be
sought from both the child, if sufficiently competent, and
parents. As part of providing consent, participants also
consent to the data and specimens being used for subse-
quent studies relevant to infection prevention and VAD
care. Serious adverse events (SAE) of mortality or ICU
admission while on the trial will be monitored and
reported to the Human Research Ethics Committee. A
data safety monitoring committee (DSMC) of two biostatis-
ticians and two medically qualified researchers (independ-
ent of the study) will review the primary end point and
SAEs after each 1000 cases. The DSMC will inform the
investigators if (1) based on the VAD-BSI rate, the sample
size needs to be significantly recalculated or (2) the study
needs to be stopped because of a statistically higher
VAD-BSI or SAE rate favouring either group.
Dissemination
Neither the sponsor nor funder will be involved in data
analysis or reporting. Data will be analysed by MRM the
study statistician. Only the research team will have access
to the study data; data generated from the trial will be
available for inspection by the HREC and funders on
request. The prevention of healthcare-associated infec-
tions and responsible use of the health dollar are of high
interest to all stakeholders, including the community. We
will present results locally, and at relevant local and inter-
national meetings of the infection control and vascular
access specialty groups, and a media release will be circu-
lated. The investigators will be available for interviews in
the community/health media and we will supply results to
organisations that publish clinical practice guidelines for
the care of patients with VADs. The study will be published
in a peer-reviewed healthcare journal. Authorship will be
consistent with the International Committee of Medical
Journal Editors’ criteria, and will be undertaken by the
investigators without the use of professional writers. The
results will have international application and should be
rapidly translated into clinical policies. During the study,
monthly investigator meetings will be held at one of the
participating hospitals, with remote sites joining by tele-
conference/videoconference. These meetings are a forum
for tracking recruitment and communicating important
protocol modificants or clarifications. These issues are also
followed up via email or telephone calls to the Local Site
Investigators/Study Nurses by the Study Managers (NMM,
EL). The study managers along with the chief investigator
(CMR) also organise regular updates and annual reports
to the Human Research Ethics Committees, local hospital
Research Governance Officers, the granting bodies and
the trial registry.
TRIAL STATUS
Recruitment of patients to the study is ongoing. The
first patient was recruited in May 2011 and it is expected
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that recruitment will be completed in December 2015.
Steady recruitment has been maintained through
regular site visits by the project manager, monthly study
meetings of all participating sites and continued educa-
tion to both clinical and study staff at each site.
Additional and replacement study sites have been added
over the course of the trial to increase participant enrol-
ment and/or to address the resignation of the local site
principle investigator, where relevant.
DISCUSSION
While good evidence exists to support AS use up to
4 days,9 there are minimal data about use beyond this
time. Approximately 14 million VADs are used each year
in Australia alone and nurses care for these devices
daily.1 Changing from 4-day to 7-day AS replacement
saved US$7425 per year per ward in a US study.17 In
Australia, each AS replacement costs up to $A300 (2004
estimate) in equipment and about 0.5 nursing hours.8 If
7-day AS use is adopted and even if four million VADs
avoided one AS replacement at $250, then $A1 billion
and 2 million nursing hours would be saved each year.
This would also incur significant reductions in plastic
waste. Evidence to date has favoured the adult intensive-
care setting and it is vital that further knowledge is gath-
ered across the spectrum of VAD use in medical, surgical,
oncology and haematology units, as well as paediatric
patients. This study will support or refute the practice of
restricting AS use to 4 days and if the safety of 7-day use is
confirmed, will change practice worldwide.
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